Robert W. Beall

Robert W. Beall

Vice President
ProPharma Group
As vice president at ProPharma Group, Robert W. Beall, has over 35 years of industry experience in cell therapy development and commercialization. He has contributed to advancements such as the decentralization of CD19+ CAR-T therapies, hospital cellular therapy lab development, and the expansion of the NIH Center for Cellular Engineering. Robert also supported the scaling of the first commercialized CAR-T therapy and led remediation and automation efforts for CAR-T manufacturing. With a proven track record of managing international product transfers across top pharmaceutical companies, he holds a BS in Engineering from the Rochester Institute of Technology (RIT) and a PMP certification.

Articles by Robert W. Beall

  • A new era in cancer care

    Thursday, March 13, 2025
    Immunotherapy has transformed the field of oncology by harnessing the immune system’s innate ability to mount targeted attacks on cancer cells. Building on this foundation, cell and gene therapies take immunotherapy to the next level by reprogramming genetic blueprints and engineering immune cells to deliver highly personalized, possibly curative treatments. Together, these innovations could dramatically improve outcomes, with the potential to transform cancer into a more manageable condition — or even eliminate it.